Roivant Sciences Ltd. · NASDAQ:ROIV
Roivant Sciences — Q2 2026 Earnings Presentation
44 slides from Roivant Sciences's earnings presentation, Nov 9, 2026
Slide 1: Financial Results and Business Update for the Quarter Ended September 30, 2026
Financial Results and Business Update for the Quarter Ended September 30, 2026 November 9, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks This presentation includes data for brepocitinib as compared to another product generated and uncertainties that could cause actual results to differ materially from those expressed
Slide 3: Agenda
Agenda LISRAYA Launch Update IMVT-1402 in D2T RA: Period 2 Data Brepocitinib in NIU: Review of Phase 3 Data Mosliciguat in PH-ILD: Review of Phase 2 Data Financial Update Q&A 3 For investor audiences only
Slide 4: Strong Execution Across The Pipeline in 2026
Strong Execution Across The Pipeline in 2026 Brepocitinib Positive Ph2 results Initiated Ph2b/3 trial Initiated Ph3 trial for LISRAYA approved Positive Ph3 results for brepocitinib in CS for brepocitinib in LPP brepocitinib in CS and launched in DM for brepocitinib in NIU Announced February 2026 Ann
Slide 5: LISRAYA Launch Update
LISRAYA Launch Update roivant
Slide 6: LISRAYA Approved August 2026
APPROVED AUGUST 2026 LISRAYA is a tyrosine kinase 2 (TYK2) and Janus kinase (JAK) inhibitor indicated for the treatment of dermatomyositis in adult patients See important LISRAYA safety information, including boxed warning, at lisrayahcp.com/pi 6 For investor audiences only For investor audiences on
Slide 7: Launch Update: CQ3 2026
Launch Update: CQ3 2026 • Strong initial demand, driven by unmet medical $31M need, physician and patient enthusiasm and launch readiness, despite only ~5 weeks of sales in the quarter • Hundreds of patients on paid drug as of September 30, many hundreds on paid drug today U.S. Net Product Revenue Q
Slide 8: IMVT-1402 in D2T RA: Period 2 Data
IMVT-1402 in D2T RA: Period 2 Data
Slide 9: IMVT-1402 Potentially Registrational Trial in ACPA+ Difficult-to-Treat RA
IMVT-1402 Potentially Registrational Trial in ACPA+ Difficult-to-Treat RA Today’s discussion will focus on the IMVT-1402 randomized withdrawal period (Period 2) Presented May ‘26 Today’s Focus Period 1: Period 2: Endpoints Inclusiona Open-label, active Blinded randomized Randomized Treatment Respond
Slide 10: Trial Schematic & Participant Disposition
Trial Schematic & Participant Disposition Period 1: Open-Label Period 2: Randomized Withdrawal Baseline Week 16 Week 16 Week 28 ACR20 Response?1 IMVT-1402 600mg (N=40) Yes (N=118) 1:1:1 IMVT-1402 600mg (N=1652) Rand. IMVT-1402 300mg (N=362) No3 (N=47) Placebo (N=41) Primary Endpoint (ACR20) Notes: 1
Slide 11: Difficult-to-Treat RA Represents an Unmet Medical Need With Few Current Treatment Options
Difficult-to-Treat Rheumatoid Arthritis (D2T RA) Represents an Unmet Medical Need With Few Current Treatment Options D2T RA Patients • Difficult-to-treat (D2T) RA patients experience inadequate or loss of response to Have Failed multiple classes of advanced therapies, including conventional DMARDs a
Slide 12: Patients With Difficult-to-Treat RA Have Substantial Morbidity and Quality of Life Impairment
Patients With Difficult-to-Treat RA Have Substantial Morbidity and Quality of Life Impairment Due to Disease Severity and Complications 43% 46 >50% 63% 45% Fully work Consultations Dependent on Require joint Report walking disabled for 10-15 per year with external help to surgeries3 disability4 year
Slide 13: Trial Enrolled a Difficult-to-Treat Population
Previously Reported Period 1 Data Trial Enrolled a Difficult-to-Treat Population: Patients Were 4L+, Having Failed Conventional Therapy and ≥2 Mechanisms of Advanced Therapies Baseline Characteristics IMVT-1402 (Period 1) Mean unless otherwise noted (N=1652) Age, years 58.7 Sex, % female, n (%) 116
Slide 14: Period 2: Distribution Across Treatment Arms at Week 16 Generally Well-Balanced
Period 2 (Weeks 16-28): Following 16 Weeks of 600mg Treatment, Distribution Across Treatment Arms at Week 16 Generally Well-Balanced IMVT-1402 600mg IMVT-1402 300mg2 Placebo N (Period 2) 40 36 41 Age, years 60.1 57.5 57.8 Sex, % female 30 (75.0%) 25 (69.4%) 31 (75.6%) Time since RA diagnosis, years
Slide 15: Period 2 Primary Endpoint: IMVT-1402 600mg Met ACR20 Response at Week 28
Period 2 (Weeks 16-28) Primary Endpoint: IMVT-1402 600mg Met the Primary Endpoint of ACR20 Response at Week 28 Period 2 ACR20 Response Rates at Week 28 100% p = 0.0139 90% ns ACR20 Response (%) 80% 70% 92.5% 60% 75.0% 75.6% 50% 0% P1: 600mg P2: 600mg P1: 600mg P2: 300mg P1: 600mg P2: Placebo (
Slide 16: IMVT-1402 600mg Continued to Demonstrate Improvements in ACR50 and ACR70
Period 2 (Weeks 16-28): IMVT-1402 600mg Continued to Demonstrate Meaningful Improvements in ACR50 and ACR70 at Week 28 Period 2 ACR50 Response Rates at Week 28 Period 2 ACR70 Response Rates at Week 28 100% 100% p = 0.0117* p = 0.1674* 90% 90% 80% 80% 70% 70% ACR70 Response (%) ACR50 Response (%) 60%
Slide 17: ACR50/70 Rates Increased From Baseline to Week 28
ACR50/70 Rates Increased From Baseline to Week 28 in Patients Who Received IMVT-1402 600mg for the Full 28-Week Treatment Period ACR50 & ACR70 for Patients Randomized to IMVT-1402 600mg for the Full 28-Week Period (N=40) 80% 70% 60% ACR Response (%) 50% 40% 77.5% 80.0% 30% 52.5% 47.5% 20% 42.5% 10%
Slide 18: Secondary Endpoints: CDAI & SDAI Scores Maintained vs. Placebo
Period 2 (Weeks 16-28) Secondary Endpoints: Patients on IMVT-1402 600mg Maintained CDAI & SDAI Scores vs. Placebo Patients Who Worsened CDAI and SDAI endpoints reflect widely used scales in clinical practice for assessing sustained response CDAI Change from Period 2 Baseline at Week 28 SDAI Change f
Slide 19: ACR20 Response Maintained Regardless of Prior JAK Inhibitor Failure
Period 2 (Weeks 16-28): Patients Maintained ACR20 Response on IMVT-1402 600mg at Week 28 Regardless of Prior JAK Inhibitor Failure Period 2 ACR20 Response Rates at Week 28 by Prior JAK Inhibitor Failure 100% Patients with prior IL-6 inhibitor failure (N=13 90% 600mg, N=13 placebo) also performed sim
Slide 20: ACR50/70 Response Maintained Regardless of Prior JAK Inhibitor Failure
Period 2 (Weeks 16-28): Patients Also Maintained ACR50/70 Response On IMVT-1402 600mg at Week 28 Regardless of Prior JAK Inhibitor Failure Period 2 ACR50 Response Rates at Week 28 by Prior Period 2 ACR70 Response Rates at Week 28 by Prior JAK Inhibitor Failure JAK Inhibitor Failure 100% 100% 90% 90%
Slide 21: Period 2 Safety: Adverse Event Rates Comparable to Placebo
Period 2 (Weeks 16-28) Safety: IMVT-1402 Demonstrated a Favorable Safety Profile With Adverse Event Rates Comparable to Placebo n (%) IMVT-1402 600mg IMVT-1402 300mg Placebo N (Period 2) 40 35 39 Any Treatment-Emergent Adverse Event (TEAE) 9 (22.5%) 10 (28.6%) 12 (30.8%) Grade ≥3 TEAE 0 0 0 Any Seri
Slide 22: Period 2 Key Takeaways & Path Forward
Period 2 Key Takeaways & Path Forward Period 2 data further support the potential for IMVT-1402 to not only induce but to maintain deep therapeutic responses in a population that has failed multiple advanced therapies FDA interaction is planned for later this year to determine the path forward regar
Slide 23: Brepocitinib in NIU: Review of Phase 3 Data
Brepocitinib in NIU: Review of Phase 3 Data
Slide 24: Non-Infectious Uveitis: Highly Morbid, Poorly Served Indication With Large Unmet Need
Non-Infectious Uveitis (NIU): Highly Morbid, Poorly Served Indication With Large Unmet Need Disease Overview leading cause approved non- of NIU patients Symptoms include: eye 3rd of blindness in the US1 1 steroid therapy (Humira)2 50% fail within 6 months pain, eye redness, distorted vision, floater
Slide 25: CLARITY Data Suggests Brepocitinib Can Achieve a New Standard for NIU Outcomes
CLARITY Data Suggests Brepocitinib Can Potentially Achieve a New Standard for NIU Treatment Outcomes Brepocitinib achieved the largest efficacy benefit ever seen for a non-steroidal therapy in NIU (time to treatment failure >48 weeks [median not reached] vs. ~12 weeks for placebo, p<0.0001), suggest
Slide 26: Cross-Trial Comparison Suggests Brepocitinib Provides Longer Prevention of Treatment Failure
Cross-Trial Comparison Suggests Brepocitinib May Provide >2x Longer Timeline for Prevention of Treatment Failure vs. Standard of Care, With Rapid Steroid Taper CLARITY-1 & CLARITY-2 (Pooled) VISUAL I 100% HR=0.24 100% HR=0.50 p<0.0001 p<0.001 ~86%* 80% 80% 78% Treatment Failure (%) Treatment Failure
Slide 27: Low Treatment Failure Rates In Overall Population and Prior TNFi Patients
Brepocitinib Shows Low Treatment Failure Rates In Overall Population As Well As For Patients With Prior TNFi Treatment OVERALL POPULATION PRIOR TNFi POPULATION CLARITY-1 & CLARITY-2 (Pooled) CLARITY-1 & CLARITY-2 (Pooled) 100% 100% ∆ 44.7%; p<0.0001 ∆ 39.4%; p<0.0001 80% 80% 78.2% 77.5% Treatment Fa
Slide 28: Significant Improvement on Key Secondary Endpoints by Week 48
Brepocitinib Delivers Statistically and Clinically Significant Improvement on Key Secondary Endpoints by Week 48 CLARITY-1 CLARITY-2 100% 100% Steroid Free Quiescence Steroid Free Quiescence (%) Steroid Free Quiescence (%) 80% ∆ 38.1%; p<0.0001 80% ∆ 45.2%; p<0.0001 Quiescence requires both eyes wit
Slide 29: Continued Momentum Across Brepocitinib Franchise
Continued Momentum Across Brepocitinib Franchise, With LISRAYA Launch, Positive CLARITY Data and Two Additional Pivotal Programs Underway Cutaneous Sarcoidosis Potential sNDA Approval Lichen Planopilaris Potential sNDA Approval Non-Infectious Uveitis Potential sNDA Approval Non-Infectious Uveitis Cu
Slide 30: Mosliciguat in PH-ILD: Review of Phase 2 Data
Mosliciguat in PH-ILD: Review of Phase 2 Data
Slide 31: PH-ILD Represents a Significant Unmet Medical Need
PH-ILD Represents a Significant Unmet Medical Need With Few Current Treatment Options 1.5-2 Years • Patients with PH-ILD have a median survival of only 1.5-2 years from diagnosis1 Median Survival • PH-ILD is a particularly severe subgroup of pulmonary hypertension with poorer prognosis and Despite B
Slide 32: Key Highlights: Mosliciguat PHocus Trial in PH-ILD
Key Highlights: Mosliciguat PHocus Trial in PH-ILD All results achieved with convenient, one breath-per-day dosing Week 24 Key Clinical Endpoints Cardiac Measures Safety & Tolerability Exploratory Analyses 1 Primary -56.3% -75.9% -22.8% 98% Placebo-adjusted PVR Placebo-adjusted Reduction in mean Of
Slide 33: Mosliciguat Met Primary Endpoint of PVR % Change at Week 16
Mosliciguat Met the Primary Endpoint Of Pulmonary Vascular Resistance % Change From Baseline at Week 16 With a 56.3% Placebo-Adjusted Reduction Highest-ever reported PVR % reduction in any randomized, controlled trial in PH PVR % Change from Baseline at Week 16 40% 100% Median (IQR) % change from ba
Slide 34: Improvement In 6MWD Continued Through Week 24
Improvement In 6MWD Observed Early and Continued To Improve Through Week 24, Reaching More Than 52 Meters Placebo-Adjusted 6MWD Change from Baseline Over Time (N=135) 60 50 LS mean difference in 6MWD (m) 40 30 +52.7 20 +44.6 +35.2 +27.9 10 +20.6 +13.2 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
Slide 35: Exploratory Analysis of Time To Clinical Worsening
Exploratory Analysis of Time To Clinical Worsening Suggests Mosliciguat Reduced Risk of Worsening By 37% Time to First Clinical Worsening 100 37% Probability of CW event-free survival 75 Risk Reduction 50 HR: 0.63 p = 0.0955 25 Time to Clinical Worsening (TTCW) defined as the first occurrence of one
Slide 36: Mosliciguat: In A League Of Its Own
Mosliciguat Mosliciguat: In A League Of Its Own Mosliciguat PVR % Reduction PH-ILD Competitors -56.3% 10% 20% 30% 40% 50% 60% 6MWD Improvement PH-ILD Competitors +52.7m 10m 20m 30m 40m 50m 60m NT-proBNP % Reduction PH-ILD Competitors -75.9% 30% 40% 50% 60% 70% 80% Cough Rate PH-ILD Competitors 12.1%
Slide 37: Phase 3 PHrontier Study Is Underway And Actively Screening
Phase 3 PHrontier Study Is Underway And Actively Screening Double-blinded, multi-center, global trial in N = ~375 PH-ILD patients Blinded Treatment Period Screening Period Week 0 24 Rapid uptitration Mosliciguat Key Inclusion Criteria to stable dose Stable dose Randomization (1:1) • Diagnosis of PH
Slide 38: Financial Update
Financial Update e roivant LLL ZZ ZT IAF + ae eee
Slide 39: Key Financial Items
Key Financial Items Select Income Statement and Non-GAAP Metrics Select Balance Sheet Metrics for the Three Months Ended September 30, 2026 as of September 30, 2026 • R&D expenses of $146M; adjusted R&D expenses of • Cash, cash equivalents and marketable securities of $137M (non-GAAP) $4.2BN as of S
Slide 40: Non-GAAP Disclosures
Non-GAAP Disclosures Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited, in thousands) Three Months Ended September Three Months Ended September 30, 30, Note 2026 2025 Note 2026 2025 Loss from continuing operations, net of tax $ (152,974) $ (166,039) Research and development expenses $
Slide 41: Rich Catalyst Calendar
Rich Catalyst Calendar Program Vant Catalyst Expected Timing Roivant pipeline growth New mid/late-stage in-licensing announcements Ongoing Brepocitinib sNDA filing for non-infectious uveitis 1H 2027 IMVT-1402 Topline data from potentially registrational trials in Graves’ disease 2027 IMVT-1402 Topli
Slide 42: High-Value Pipeline, Delivering Series of Near-Term Catalysts
High-Value Pipeline, Delivering Series of Near-Term Catalysts Phase 1 Phase 2 Registrational Approved Brepocitinib DM Approved August 2026 NIU sNDA filing 1H 2027 CS Topline data 2028 LPP Phase 2b/3 FPFV 1Q 2026 IMVT-1402 D2T RA Positive period 2 data GD Topline data 2027 MG Topline data 2027 CIDP T
Slide 43: Investor Day 2026 Registration Link
https://roivant-investor-day-2026.open-exchange.net/registration For investor audiences only
Slide 44: Thank you.
Thank you. roivant